인플루엔자 바이러스에 대한 높은 처리량 검출 방법

Executive Industry Relevance

This infrared dye-based assay enables high-throughput quantification of influenza viral titers from clinical samples, supporting rapid strain identification and pandemic response. The method provides precise, reproducible measurements with minimal sample volume, facilitating scalable screening workflows. Its compatibility with 96- and 384-well formats allows integration into automated discovery pipelines for antiviral lead identification and mechanistic de-risking.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying viral load as a functional readout of antiviral efficacy.
• Operational Value: Supports biological de-risking through objective, titer-dependent fluorescence measurements that reduce mechanistic ambiguity.
• Predictive Value: Generates quantitative data for portfolio triage by correlating viral titer reduction with compound activity in preclinical models.

Screening & Assay Development

• Assay Readiness: Produces standardized, reproducible outputs suitable for high-throughput screening of compound libraries against influenza.
• Scalability: Compatible with 96- and 384-well plate formats, enabling concurrent screening of thousands of samples per run.
• Quantitative Output: Generates fluorescence intensity data that directly correlates with viral titer, supporting dose-response curve construction and IC50 determination.

Translational & Preclinical Research

• Disease Relevance: Uses MDCK cells infected with clinical BAL fluid to model human respiratory infection, enhancing translational validity.
• Preclinical Continuity: Enables longitudinal tracking of viral load from discovery through preclinical validation, supporting risk-adjusted advancement decisions.
• Biomarker Alignment: Viral titer serves as a mechanistic biomarker for evaluating antiviral candidates in vivo and in vitro.

Pipeline & Workflow Integration

The method fits within the antiviral discovery continuum from early target validation through lead optimization to preclinical efficacy testing, providing a quantitative bridge between in vitro screening and in vivo outcomes.

• Discovery Biology: Supports hypothesis testing by measuring viral protein expression as a direct readout of infection status and compound effect.
• Screening: Enables assay standardization and reproducibility across large compound sets, reducing false positives and negatives in primary screens.
• Analytics: Delivers integrated intensity measurements that allow statistical comparison of conditions and calculation of signal-to-noise ratios for assay quality control.
• Translational Research: Connects in vitro antiviral activity to in vivo viral load reduction, supporting biomarker-driven go/no-go decisions.
• Enterprise Reuse: Establishes a reusable infrared imaging capability applicable to multiple respiratory viruses beyond influenza, maximizing platform utility.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence in antiviral efficacy through precise, linear quantification of viral titers across a wide dynamic range.
• Operational Value: Ensures standardization and reproducibility via infrared detection that minimizes autofluorescence and batch variability.
• Strategic Value: Improves capital efficiency by enabling early go/no-go decisions based on quantitative antiviral activity, reducing late-stage failure risk.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates by correlating in vitro titer reduction with in vivo efficacy predictors.

Implementation Considerations

• Requires expertise in virology, cell culture, and immunofluorescence techniques for proper assay execution and interpretation.
• Dependent on Licor Odyssey infrared scanner and associated software for signal acquisition and quantification.
• Necessitates standardization of antibody dilutions, incubation times, and washing protocols across users and sites.
• Must account for cell line variability and viral strain differences when adapting the assay to other pathogens or models.
• Limited to detecting viral proteins; cannot distinguish between infectious and non-infectious particles without complementary assays.

Biopharma FAQs